Treatment choices and neuropsychological symptoms of a large cohort of early MS

Olga von Bismarck; Theresa Dankowski; Björn Ambrosius; Nicole Hessler; Gisela Antony; Andreas Ziegler; Muna-Miriam Hoshi; Lilian Aly; Felix Luessi; Sergiu Groppa; Luisa Klotz; Sven G Meuth; Björn Tackenberg; Muriel Stoppe; Florian Then Bergh; Hayrettin Tumani; Tania Kümpfel; Martin Stangel; Christoph Heesen; Brigitte Wildemann; Friedemann Paul; Antonios Bayas; Clemens Warnke; Frank Weber; Ralf A Linker; Ulf Ziemann; Uwe K Zettl; Frauke Zipp; Heinz Wiendl; Bernhard Hemmer; Ralf Gold; Anke Salmen

doi:10.1212/NXI.0000000000000446

Treatment choices and neuropsychological symptoms of a large cohort of early MS

Olga von Bismarck, Theresa Dankowski, Björn Ambrosius, Nicole Hessler, Gisela Antony, Andreas Ziegler, Muna-Miriam Hoshi, Lilian Aly, Felix Luessi, Sergiu Groppa, Luisa Klotz, Sven G Meuth, Björn Tackenberg, Muriel Stoppe, Florian Then Bergh, Hayrettin Tumani, Tania Kümpfel, Martin Stangel, Christoph Heesen, Brigitte WildemannFriedemann Paul, Antonios Bayas, Clemens Warnke, Frank Weber, Ralf A Linker, Ulf Ziemann, Uwe K Zettl, Frauke Zipp, Heinz Wiendl, Bernhard Hemmer, Ralf Gold, Anke Salmen

University of Marburg

Abstract

Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.

Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.

Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.

Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.

Original language	English
Journal	Neurology(R) neuroimmunology & neuroinflammation
Volume	5
Issue number	3
Pages (from-to)	e446
ISSN	2332-7812
DOIs	https://doi.org/10.1212/NXI.0000000000000446
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1212/NXI.0000000000000446

Cite this

von Bismarck, O., Dankowski, T., Ambrosius, B., Hessler, N., Antony, G., Ziegler, A., Hoshi, M-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Then Bergh, F., Tumani, H., Kümpfel, T., Stangel, M., Heesen, C., ... Salmen, A. (2018). Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology(R) neuroimmunology & neuroinflammation, 5(3), e446. https://doi.org/10.1212/NXI.0000000000000446

@article{01bd9f0ef9e3449a960dd0be4a3888ea,

title = "Treatment choices and neuropsychological symptoms of a large cohort of early MS",

abstract = "Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.",

author = "{von Bismarck}, Olga and Theresa Dankowski and Bj{\"o}rn Ambrosius and Nicole Hessler and Gisela Antony and Andreas Ziegler and Muna-Miriam Hoshi and Lilian Aly and Felix Luessi and Sergiu Groppa and Luisa Klotz and Meuth, {Sven G} and Bj{\"o}rn Tackenberg and Muriel Stoppe and {Then Bergh}, Florian and Hayrettin Tumani and Tania K{\"u}mpfel and Martin Stangel and Christoph Heesen and Brigitte Wildemann and Friedemann Paul and Antonios Bayas and Clemens Warnke and Frank Weber and Linker, {Ralf A} and Ulf Ziemann and Zettl, {Uwe K} and Frauke Zipp and Heinz Wiendl and Bernhard Hemmer and Ralf Gold and Anke Salmen",

year = "2018",

doi = "10.1212/NXI.0000000000000446",

language = "English",

volume = "5",

pages = "e446",

journal = "Neurology(R) neuroimmunology & neuroinflammation",

issn = "2332-7812",

number = "3",

}

von Bismarck, O, Dankowski, T, Ambrosius, B, Hessler, N, Antony, G, Ziegler, A, Hoshi, M-M, Aly, L, Luessi, F, Groppa, S, Klotz, L, Meuth, SG, Tackenberg, B, Stoppe, M, Then Bergh, F, Tumani, H, Kümpfel, T, Stangel, M, Heesen, C, Wildemann, B, Paul, F, Bayas, A, Warnke, C, Weber, F, Linker, RA, Ziemann, U, Zettl, UK, Zipp, F, Wiendl, H, Hemmer, B, Gold, R & Salmen, A 2018, 'Treatment choices and neuropsychological symptoms of a large cohort of early MS', Neurology(R) neuroimmunology & neuroinflammation, vol. 5, no. 3, pp. e446. https://doi.org/10.1212/NXI.0000000000000446

TY - JOUR

T1 - Treatment choices and neuropsychological symptoms of a large cohort of early MS

AU - von Bismarck, Olga

AU - Dankowski, Theresa

AU - Ambrosius, Björn

AU - Hessler, Nicole

AU - Antony, Gisela

AU - Ziegler, Andreas

AU - Hoshi, Muna-Miriam

AU - Aly, Lilian

AU - Luessi, Felix

AU - Groppa, Sergiu

AU - Klotz, Luisa

AU - Meuth, Sven G

AU - Tackenberg, Björn

AU - Stoppe, Muriel

AU - Then Bergh, Florian

AU - Tumani, Hayrettin

AU - Kümpfel, Tania

AU - Stangel, Martin

AU - Heesen, Christoph

AU - Wildemann, Brigitte

AU - Paul, Friedemann

AU - Bayas, Antonios

AU - Warnke, Clemens

AU - Weber, Frank

AU - Linker, Ralf A

AU - Ziemann, Ulf

AU - Zettl, Uwe K

AU - Zipp, Frauke

AU - Wiendl, Heinz

AU - Hemmer, Bernhard

AU - Gold, Ralf

AU - Salmen, Anke

PY - 2018

Y1 - 2018

N2 - Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.

AB - Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively.Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.

U2 - 10.1212/NXI.0000000000000446

DO - 10.1212/NXI.0000000000000446

M3 - Journal articles

C2 - 29511705

SN - 2332-7812

VL - 5

SP - e446

JO - Neurology(R) neuroimmunology & neuroinflammation

JF - Neurology(R) neuroimmunology & neuroinflammation

IS - 3

ER -

Treatment choices and neuropsychological symptoms of a large cohort of early MS

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this